Paradigm Biopharmaceuticals Ltd. (AU:PAR)

ASX:PAR

PAR

Paradigm Biopharmaceuticals

RESEARCH TOOLSreports

Want to see AU:PAR full AI Analyst Report?

Paradigm Biopharmaceuticals (PAR) Price & Analysis

42 Followers

PAR Stock Chart & Stats

AU$0.33

-AU$0.03(-5.32%)

At close: Jan 09 4:00 PM EST

AU$0.33

-AU$0.03(-5.32%)

Day’s Range― - ―

52-Week RangeAU$0.14 - AU$0.48

Previous CloseN/A

Volume3.26M

Average Volume (3M)841.61K

Market Cap

AU$86.47M

Enterprise ValueAU$57.86M

Total Cash (Recent Filing)AU$14.66M

Total Debt (Recent Filing)AU$1.01M

Price to Earnings (P/E)―

Beta2.50

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding576,499,270

10 Day Avg. Volume720,106

30 Day Avg. Volume841,610

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.53

Price to Sales (P/S)1840.42

P/FCF Ratio-6.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.1

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageA conservatively levered balance sheet reduces refinancing and interest-rate risk for a cash-burning biotech. Low debt preserves capacity to raise capital via equity or partnerships, supporting long-term investment in trials, approvals and commercialization without immediate solvency pressure.

Improving Cash OutflowA marked reduction in operating cash outflows signals improving cost discipline or operational efficiency. If sustained, lower burn extends runway, reduces near-term funding needs and increases chances that business milestones can be reached before dilutive financing is required.

Commercialization-based Revenue ModelA core revenue model built on prescription product sales, plus licensing and distribution partnerships, provides multiple scalable commercial paths. This mix can generate recurring sales and non-dilutive milestone or royalty income as products gain market traction.

Bears Say

Persistent Negative Cash FlowOngoing negative operating and free cash flow indicates the business cannot self-fund operations or growth. Reliance on external capital is likely to persist, increasing dilution risk and constraining long-term R&D, regulatory and commercial investments if funding conditions tighten.

Small, Volatile RevenueA tiny and inconsistent revenue base limits ability to achieve scale, absorb fixed costs, or generate sustainable margins. Volatility makes forecasting, pricing leverage and reinvestment planning difficult, prolonging the timeline to profitability and commercial stability.

Declining Equity & Negative ROEMaterial equity erosion and persistently negative ROE reflect continuing value destruction from losses. This weakens the capital base, can increase cost of capital, and complicates fundraising or partnership negotiations needed to finance ongoing development and commercialization.

Paradigm Biopharmaceuticals News

Paradigm Director Increases Stake via Share Purchase Plan

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has disclosed a change in director Matthew...

10d ago

Paradigm Director Paul Rennie Increases Stake Through Additional Share Purchases

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has announced changes to the interests of...

10d ago

Paradigm Biopharmaceuticals Redeems Over 1.3 Million Convertible Notes

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals Limited has announced the cessation...

12d ago

Paradigm Biopharmaceuticals Seeks Quotation for 7.7 Million New Shares on ASX

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

13d ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for 43.4 Million New Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

14d ago

Paradigm Biopharmaceuticals Corrects Share Purchase Plan Details in ASX Filing

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has updated its disclosure to the ASX...

15d ago

Paradigm Secures $21.35m After Oversubscribed Share Purchase Plan

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals has completed an oversubscribed Share Purchase Plan...

15d ago

Paradigm Biopharmaceuticals sets June in‑person shareholder meeting with digital proxy push

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has called a General Meeting of shareholders...

1M ago

Paradigm Completes Institutional Placement and Prepares Share Purchase Plan

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals has completed a placement of 73,684,211 fully...

2M ago

Paradigm Biopharmaceuticals Seeks Quotation for 73.7 Million New Shares on ASX

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

2M ago

PAR FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.14 and its highest was AU$0.48 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is AU$86.47M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 67 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.056.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 576,499,270 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:PAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Underperform

Blogger Sentiment

Bullish

AU:PAR Sentiment 87%
Sector Average ―

Technicals

Fundamentals

Return on Equity

-265.55%

Trailing 12-Months

Asset Growth

-29.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.